Integra Lifesciences Holdings Corp
NASDAQ:IART

Watchlist Manager
Integra Lifesciences Holdings Corp Logo
Integra Lifesciences Holdings Corp
NASDAQ:IART
Watchlist
Price: 12.01 USD -3.3% Market Closed
Market Cap: 935.5m USD

Integra Lifesciences Holdings Corp
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Integra Lifesciences Holdings Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Integra Lifesciences Holdings Corp
NASDAQ:IART
EPS (Diluted)
-$6
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-91%
Becton Dickinson and Co
NYSE:BDX
EPS (Diluted)
$5
CAGR 3-Years
0%
CAGR 5-Years
17%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
EPS (Diluted)
$1
CAGR 3-Years
64%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
EPS (Diluted)
$7
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
EPS (Diluted)
$8
CAGR 3-Years
21%
CAGR 5-Years
34%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
EPS (Diluted)
$7
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

Integra Lifesciences Holdings Corp
Glance View

Market Cap
934.8m USD
Industry
Health Care

Integra LifeSciences Holdings Corp., an influential player in the medical technology landscape, traces its origins back to a vision of creating life-enhancing innovations for surgical procedures. Founded in the late 1980s, Integra has evolved into a formidable presence, driven by a commitment to delivering solutions that improve patient outcomes in regenerative medicine and surgical care. The company operates primarily through two segments: the Codman Specialty Surgical and the Tissue Technologies segment. By focusing on these two areas, Integra leverages its expertise in surgical tools, neurocritical care, and advanced wound care, appealing to healthcare professionals worldwide. This strategic segmentation enables the company to cater to a diverse clientele, encompassing hospitals and other medical institutions in North America, Europe, and internationally. Integra's revenue streams are notably derived from the design, manufacture, and distribution of a comprehensive suite of products used in neurosurgery, acute wound care, and reconstructive surgery. The company's innovative products, including precision surgical instruments and biologics that promote regenerative tissue healing, are key contributors to its financial success. By continuously investing in research and development, Integra ensures the introduction of cutting-edge solutions that address the evolving needs of the healthcare industry. The company's growth strategy hinges on both organic innovation and strategic acquisitions, fostering an environment where technological advancements seamlessly integrate with expanding market reach. This symbiotic approach not only solidifies Integra's position in the med-tech arena but also underpins its growth potential in an ever-competitive healthcare sector.

IART Intrinsic Value
38.03 USD
Undervaluation 68%
Intrinsic Value
Price

See Also

What is Integra Lifesciences Holdings Corp's EPS (Diluted)?
EPS (Diluted)
-6.5 USD

Based on the financial report for Sep 30, 2025, Integra Lifesciences Holdings Corp's EPS (Diluted) amounts to -6.5 USD.

What is Integra Lifesciences Holdings Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-91%

Over the last year, the EPS (Diluted) growth was -7 078%.

Back to Top